BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30195076)

  • 21. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
    Wehrle J; von Bubnoff N
    Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ponatinib (Iclusig) for CML and Ph+ ALL.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
    Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ponatinib: a third-generation inhibitor for the treatment of CML.
    Wehrle J; Pahl HL; von Bubnoff N
    Recent Results Cancer Res; 2014; 201():99-107. PubMed ID: 24756787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
    Santoro M; Accurso V; Mancuso S; Contrino AD; Sardo M; Novo G; Di Piazza F; Perez A; Russo A; Siragusa S
    Chemotherapy; 2019; 64(4):205-209. PubMed ID: 31825920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation.
    Goodrich AD
    Expert Rev Hematol; 2014 Oct; 7(5):513-5. PubMed ID: 25199408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic myeloid leukemia harboring T315I and F317L mutations successfully treated with interferon-α and ponatinib].
    Motomura Y; Arai K; Yoshifuji K; Sonokawa S; Suzuki S; Kumagai T
    Rinsho Ketsueki; 2019; 60(1):33-38. PubMed ID: 30726822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
    Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
    Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.
    Tachibana T; Koyama S; Andou T; Ishiyama Y; Tanaka M; Nakajima H; Kanamori H
    Int J Hematol; 2019 Feb; 109(2):162-168. PubMed ID: 30511314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 35. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
    Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
    Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
    Sacha T; Szczepanek E; Dumnicka P; Góra-Tybor J; Niesiobędzka-Krężel J; Prejzner W; Wasilewska E; Kłoczko J; Ciepłuch H; Makowska W; Patkowska E; Wasilewska J; Bober G; Kopera M; Wichary R; Kroll-Balcerzak R; Gromek T; Wach M; Rudkowska-Kazanowska A; Świniarska M; Paczkowska E; Biernat M; Joks M; Oller M; Kasza R; Kostyra A; Gil J; Grzybowska-Izydorczyk O
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):405-415. PubMed ID: 34933827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.